hotspot -WSS

hotspot

author：focus 2025-09-06 03:53:16 - browse：269

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Dems pitch expanding Medicare power to negotiate drug prices

focus

WSS

CDC concerned about possible undetected monkeypox spread in U.K.

'Investigate these claims': UFO transparency at center of House hearing

The science behind Janet Jackson's pregnancy at 49

Biden warns of ‘dark winter’ during final presidental debate

Disclosing genetic information: not as worrisome as once feared

Device maker Teleflex to acquire urology company for $600M

focus

hotspot

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Hollywood unions extend contract negotiations for actors

The strategy behind pharma's lawsuits over drug pricing reform

Medicare proposal to cover medical devices draws a mixed reaction

A new crop of companies is reshaping the health data economy

Jerome Adams on the need for new antivirals for Covid

Death of patient in Alzheimer’s trial raises question of possible risks

State Dept. review finds Biden bears some blame for Afghanistan failures

The science behind Janet Jackson's pregnancy at 49

focus

What causes rare myocarditis in young men after Covid vaccines?

'Investigate these claims': UFO transparency at center of House hearing

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

In areas with more Black doctors, Black people live longer

Search called off for baby washed away in Pennsylvania flash flood

WATCH: Why do fingernails fall off when they're damaged?

entertainment

focus

entertainment

leisure time